Garry, E M <br/><br/>
Activation of p38 and p42/44 MAP kinase in neuropathic pain: involvement of VPAC2 and NK2 receptors and mediation by spinal glia.  [electronic resource] 

 -  Molecular and cellular neurosciences  Dec 2005 
 - 523-37 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1044-7431 
<br/><br/><label>Standard No.: </label>10.1016/j.mcn.2005.08.016  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Disease Models, Animal<br/>Enzyme Activation--drug effects<br/>Enzyme Inhibitors--pharmacology<br/>Inflammation Mediators--pharmacology<br/>MAP Kinase Signaling System--drug effects<br/>Male<br/>Mitogen-Activated Protein Kinase 1--drug effects<br/>Neuralgia--metabolism<br/>Neuroglia--drug effects<br/>Neuroprotective Agents--pharmacology<br/>Peripheral Nerve Injuries<br/>Peripheral Nerves--metabolism<br/>Peripheral Nervous System Diseases--metabolism<br/>Phosphorylation--drug effects<br/>Physical Stimulation<br/>Posterior Horn Cells--drug effects<br/>Rats<br/>Rats, Wistar<br/>Receptors, N-Methyl-D-Aspartate--drug effects<br/>Receptors, Neurokinin-2--drug effects<br/>Receptors, Vasoactive Intestinal Peptide, Type II--drug effects<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors<br/>Xanthines--pharmacology<br/>p38 Mitogen-Activated Protein Kinases--drug effects